Precision Glycobiology Disease Models: Building the Blueprint for Better Health

Protein glycosylation involves the connection between glycans and protein molecules, which is necessary for the correct folding of protein molecules, maintaining stability, participating in interactions and cell adhesion, etc. Abnormal glycosylation leads to the occurrence of many major human diseases, such as leukemia, pancreatic dysfunction, Alzheimer's disease, etc. In the study of diseases induced by abnormal glycosylation, choosing a suitable animal model helps explore the occurrence and development mechanism of the disease and develop effective therapeutic drugs. CD BioGlyco provides a variety of stable and high-quality Glycobiology Disease Model Development Services to help clients achieve their goals.

We have other disease model construction services to assist you in studying tumors, aging, pain, liver disease, lung disease, and sepsis. Our services are as follows:

• Oncology Model Construction Service

The glycan-related genes of mice are modified through genetic engineering technology to study tumor growth, spread, and response to treatment.

• Aging Model Construction Service

Abnormal glycosylation patterns are associated with aging. We use gene editing technology to help clients modify and transform certain glycosyltransferases to construct aging mouse models to study the complex glycosylation changes of glycans during aging.

• Pain Model Construction Service

Carrageenan is a polysaccharide extracted from red algae, which induces local inflammation and hyperalgesia when injected into animal tissues. We use rodents such as mice or rats to screen anti-inflammatory and analgesic drugs by injecting a certain amount of carrageenan subcutaneously into the paw.

• Liver Disease Model Construction Service

Non-alcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma are all associated with abnormal glycosylation. We help clients knock out or change specific genes in model mice through gene editing to simulate liver disease. Injection of chemicals such as carbon tetrachloride (CCl₄) or thioacetamide is used to induce liver fibrosis to study glycosylation changes.

• Acute Lung Injury Model Construction Service

Lipopolysaccharide (LPS) is a major component of the outer membrane of gram-negative bacteria and triggers a strong inflammatory response when introduced into the body. LPS induces pulmonary edema and hemorrhage when injected intratracheally or intraperitoneally into rodents and is used to study the molecular and cellular mechanisms behind acute lung injury.

• LPS-induced Sepsis Model Construction Service

LPS-induced sepsis is a commonly used model to study the pathophysiology and potential therapeutic measures of sepsis. LPS is administered to mice or rats via intraperitoneal, intravenous, or subcutaneous injection, which causes immune system activation, resulting in the release of cytokines such as TNF-alpha, IL-1beta, and IL-6, leading to systemic inflammation.

Publication

Applications

• Study the role of glycosylation in tumorigenesis and metastasis, and screen and develop potential therapeutics targeting pathways related to abnormal glycosylation.
• Explore the role of glycans in aging and chronic pain, and identify and validate potential biomarkers.
• Create models to study glycan-pathogen interactions in liver and lung diseases.
• Develop therapeutic strategies for diseases related to glycobiology.

Advantages of Us

• We not only provide stable and reliable autoimmune and inflammatory models, gastrointestinal disease models, cardiovascular models, kidney disease models, and fibrosis disease models but also reliable technologies for building animal models of tumors, aging, pain, liver disease, lung disease, LPS-induced sepsis, etc.
• Professional technology and expertise in glycan analysis help us speed up the model development process and reduce the long-term costs associated with erroneous research work.
• The disease models we build have the advantages of good stability and high accuracy, making the research more reliable.
• Multiple technologies such as gene editing and gene expression, combined with glycomics and glycoproteomics platforms provide you with a holistic view of the disease model.

Frequently Asked Questions

• What technologies can be used to construct disease models?

At CD BioGlyco, we help clients construct disease models using these technologies, including but not limited to gene editing (such as knock-in, knock-down, and knock-out), transgenic, embryo implantation and cultivation, selective breeding, and gene expression.

• What diseases can the constructed animal models be used to study?

At CD BioGlyco, we construct animal models for the study of the following diseases, including but not limited to autoimmunity and inflammation (rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, diabetes mellitus), gastrointestinal disease, cardiovascular, kidney disease, fibrosis disease, and other disease.

CD BioGlyco provides competitive glycobiology disease model construction services to clients around the world, enabling scientists to study the molecular mechanisms of glycobiology diseases in the laboratory and develop effective treatment strategies. Please feel free to contact us for more information on glycobiology disease model construction.